liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial
Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway; Faculty of Medicine, K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research, University of Oslo, Oslo, Norway.
Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark.
Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
Department of Respiratory Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
Show others and affiliations
2016 (English)In: Transplant International, ISSN 0934-0874, E-ISSN 1432-2277, Vol. 29, no 7, 819-829 p.Article in journal (Refereed) Published
Abstract [en]

The NOCTET study randomized 282 patients ≥1 year after heart or lung transplantation to continue conventional calcineurin inhibitor (CNI) therapy or to start everolimus with reduced-exposure CNI. Last follow-up, at ≥5 years postrandomization (mean: 5.6 years) was attended by 72/140 everolimus patients (51.4%) and 91/142 controls (64.1%). Mean measured GFR remained stable in the everolimus group from randomization (51.3 ml/min) to last visit (51.4 ml/min) but decreased in controls (from 50.5 ml/min to 45.3 ml/min) and was significantly higher with everolimus at last follow-up (P = 0.004). The least squares mean (SE) change from randomization was -1.5 (1.7)ml/min with everolimus versus -7.2 (1.7)ml/min for controls (difference: 5.7 [95% CI 1.7; 9.6]ml/min; P = 0.006). The difference was accounted for by heart transplant patients (difference: 6.9 [95% 2.3; 11.5]ml/min; P = 0.004). Lung transplant patients showed no between-group difference at last follow-up. Rates of rejection, death, and major cardiac events were similar between groups, as was graft function. Pneumonia was more frequent with everolimus (18.3% vs. 6.4%). In conclusion, introducing everolimus in maintenance heart transplant patients, with reduced CNI, achieves a significant improvement in renal function which is maintained for at least 5 years, but an early renal benefit in lung transplant patients was lost. Long-term immunosuppressive efficacy was maintained.

Place, publisher, year, edition, pages
Wiley-Blackwell Publishing Inc., 2016. Vol. 29, no 7, 819-829 p.
Keyword [en]
calcineurin inhibitor, certican, cyclosporine, everolimus, heart, lung, randomized, renal impairment, tacrolimus, transplantation
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-130205DOI: 10.1111/tri.12783ISI: 000379691200009PubMedID: 27067532OAI: diva2:948976

Funding agencies: Novartis Scandinavia

Available from: 2016-07-14 Created: 2016-07-14 Last updated: 2016-08-15Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Jansson, Kjell
By organisation
Division of Cardiovascular MedicineFaculty of Medicine and Health SciencesDepartment of Cardiology in Linköping
In the same journal
Transplant International
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 23 hits
ReferencesLink to record
Permanent link

Direct link